Clinical trials: Lymphoid Neoplasms
Chronic Lymphocytic Leukemia (CLL)
informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia
The study is designed as a multicenter, prospective, observational registry of CLL/SLL patients who are initiating approved oral kinase inhibitors, BCL-2 inhibitors or other approved anti-CLL therapies/regimens.
- Trial name
- informCLL (NCT02582879)
- Where
- 192 sites in United States
- Volunteers
- 1,504 people
- Sponsor
- Pharmacyclics LLC.
Chronic Lymphocytic Leukemia
CLL Therapy Approaches in Russia
This is going to be a non-interventional study (NIS). Assessment of variables will be carried out using data on patient's treatment in real-life clinical setting.
- Trial name
- CLL registry (NCT05140369)
- Where
- 34 sites in Russia
- Volunteers
- 6,000 people
- Sponsor
- AstraZeneca
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell
A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice
The purpose of this study is to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy for chronic lymphocytic leukemia (CLL) and mantle-cell…
- Trial name
- FIRE (NCT03425591)
- Testing
- Ibrutinib
- Where
- France
- Volunteers
- 508 people
- Sponsor
- Janssen-Cilag Ltd.
Leukemia, Lymphoma, Large B-Cell, Diffuse
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
This is a single arm study to evaluate the efficacy and safety of CD19-targeted CAR-T cells therapy for patients with relapsed/refractory CD19+ B Cell Leukemia and Lymphoma.
- Conditions
- Leukemia, Lymphoma, Large B-Cell, Diffuse, Leukemia, B-cell, Lymphoma, B-Cell
- Trial name
- NCT04271410
- Testing
- CD19 CAR-T cells
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Chronic Lymphocytic Leukemia
SPC2996 in Chronic Lymphocytic Leukaemia
The purpose of this study is to determine whether SPC2996 is effective and safe in the treatment of Chronic Lymphocytic Leukaemia (CLL)
- Trial name
- NCT00285103
- Testing
- SPC2996
- Where
- 12 sites in United States, Denmark and 2 more
- Volunteers
- 46 people
- Sponsor
- Santaris Pharma A/S
Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL)
Study of the Glutaminase Inhibitor CB-839 in Leukemia
Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival.
- Trial name
- NCT02071927
- Testing
- CB-839, CB-Aza
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- Calithera Biosciences, Inc
ACUTE LYMPHOBLASTIC LEUKEMIA
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
This prospective, randomized, multicenter, open-label Phase 2 study is designed to evaluate the superiority of InO monotherapy vs ALLR3 after 1 cycle of induction treatment in paediatric participants (between 1 and <18 years)…
- Trial name
- NCT05748171
- Testing
- Inotuzumab ozogamicin, ALLR3
- Where
- 65 sites in Austria, Belgium and 13 more
- Volunteers
- 100 people
- Sponsor
- Pfizer
Chronic Lymphocytic Leukemia (CLL), Lymphoma, Non-Hodgkin (NHL)
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
The purpose of this study is to determine the dose that can be safely given to see what effect it may have on your cancer and to determine how the drug is distributed in the body.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Lymphoma, Non-Hodgkin (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM)
- Trial name
- NCT00710528
- Testing
- CAL-101
- Where
- 9 sites in United States
- Volunteers
- 192 people
- Sponsor
- Gilead Sciences
Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome
RPM Signals in Outpatient CAR T Therapy
The goal of this observational study is to learn how patients' vital signs and symptoms change during outpatient CAR T-cell therapy with lisocabtagene maraleucel (liso-cel), a type of cancer treatment.
- Conditions
- Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome, B-Cell Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT07882732
- Volunteers
- 125 people
- Sponsor
- Current Health
Leukemia, Lymphoma, Chronic Lymphocytic, Leukemia, Prolymphocytic Leukemia, Small
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia
This was a multicenter, Phase 1, standard 3+3 dose-escalation study to evaluate the safety and anti-neoplastic activity of moxetumomab pasudotox in relapsed or refractory participants with chronic lymphocytic leukemia (CLL)…
- Conditions
- Leukemia, Lymphoma, Chronic Lymphocytic, Leukemia, Prolymphocytic Leukemia, Small, Lymphocytic Lymphoma, Moxetumomab Pasudotox
- Trial name
- NCT00587457
- Testing
- CAT-8015 5 mcg/kg, CAT-8015 10 mcg/kg, CAT-8015 20 mcg/kg
- Where
- 3 sites in United States, Poland
- Volunteers
- 11 people
- Sponsor
- MedImmune LLC
Leukaemia, Lymphocytic, Chronic
Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia
The purpose of this study was to evaluate the safety and efficacy of ofatumumab added to fludarabine-cyclophosphamide in patients with relapsed Chronic Lymphocytic Leukemia (CLL).
- Trial name
- NCT00824265
- Testing
- OFC Infusion, FC infusion
- Where
- 135 sites in United States, Brazil and 16 more
- Volunteers
- 365 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia
A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
This is an open-label, multicenter, Phase I/II study of the safety of escalating doses of single-agent PRO131921 in patients with chronic lymphocytic leukemia (CLL) who have relapsed after or were refractory to treatment with a…
- Trial name
- NCT00496132
- Testing
- PRO131921
- Volunteers
- 16 people
- Sponsor
- Genentech, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia
The purpose of this study is to assess the safety and tolerability of different doses of XL844 when given orally to adults with recurrent or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Trial name
- NCT00234481
- Testing
- XL844
- Where
- 3 sites in United States
- Sponsor
- Exelixis
Chronic Lymphocytic Leukemia
A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 under two different dosing schedules with the objective of defining the dose limiting toxicity and maximum tolerated dose.
- Trial name
- NCT00481091
- Testing
- ABT-263
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 60 people
- Sponsor
- AbbVie
Anemia, Healthy
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
The purpose study is to report on the accuracy of noninvasive hemoglobin (SpHb) as compared to hemoglobin measurements obtained from a laboratory hematology analyzer.
- Conditions
- Anemia, Healthy, Pediatric ALL
- Trial name
- NCT02930850
- Testing
- Rad-67 Pulse oximeter
- Where
- 7 sites in United States
- Volunteers
- 447 people, healthy volunteers welcome
- Sponsor
- Masimo Corporation
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)
This is a prospective, multicenter, non-interventional study to test the safety and effectiveness of MabThera administered subcutaneously in participants with NHL or CLL. The length of study is expected to be 6 years.
- Trial name
- NCT03289182
- Testing
- MabThera
- Where
- 25 sites in South Korea
- Volunteers
- 701 people
- Sponsor
- Hoffmann-La Roche
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
- Trial name
- NCT03893682
- Testing
- CG-806
- Where
- 30 sites in United States
- Volunteers
- 36 people
- Sponsor
- Aptose Biosciences Inc.
Lymphoma, Low-Grade, Lymphoma, Small Lymphocytic
Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma
The aim of this trial is to determine the appropriate dose of pixantrone to be used in this combination and obtain data on the combination's safety and activity profile.
- Conditions
- Lymphoma, Low-Grade, Lymphoma, Small Lymphocytic, Lymphoma, Mixed-Cell, Follicular, Lymphoma, Small Cleaved-Cell, Follicular
- Trial name
- NCT00060684
- Testing
- Pixantrone (BBR 2778), fludarabine, dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- CTI BioPharma
Acute Lymphocytic Leukemia Refractory, Lymphoma, Lymphoblastic
A Study of CTD402 in T-ALL/LBL Patients
The goal of the TENACITY-01 clinical trial is to learn if CTD402 UCART is safe and effective for relapsed/refractory T-ALL/LBL patients.
- Trial name
- TENACITY-01 (NCT07070219)
- Testing
- CTD402 CAR T Cell Injection
- Where
- 9 sites in United States, Australia
- Volunteers
- 118 people
- Sponsor
- Imviva Bio
B-Cell Chronic Lymphocytic Leukemia
Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy
The purpose of this study is to assess the effect of a moderate Cytochrome P450 (CYP) 3A inhibitor (erythromycin) and a strong CYP3A inhibitor (voriconazole) on the steady-state pharmacokinetics (PK [the study of the way a drug…
- Trial name
- NCT02381080
- Testing
- Ibrutinib, Erythromycin, Voriconazole
- Where
- 6 sites in Canada, Russia and 1 more
- Volunteers
- 26 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.